This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Thomas C. Chalmers, MD

JAMA. 1975;231(6):624-625.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A long-awaited assessment of the validity of the indictment of oral hypoglycemic agents by the University Group Diabetes Program (UGDP)¹ is appearing in this issue. Because the controversy stirred up by the report centered around the biostatistical aspects of this and other long-term trials of the oral agents, the Director of the National Institutes of Health (NIH) contracted with the prestigious Biometric Society to appoint a committee of distinguished biostatisticians to review the pertinent studies in detail. This has now been accomplished in a most thorough manner. The overall judgment of the experts is that the shortcomings of the UGDP study are not sufficient to invalidate the results, and these are not contradicted by the other studies. The probability that oral hypoglycemic agents cause premature deaths from cardiovascular disease remains valid.

Statistically valid studies do not prove anything. They merely give the practitioner a probability estimate on which to . . . [Full Text PDF of this Article]

Author Affiliations
Mount Sinai Medical Center New York

Footnotes
Address editorial communications to the Editor, 535 N Dearborn St, Chicago 60610

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?